IBDEI0NF ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10704,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,10704,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,10705,0)
 ;;=C94.41^^68^675^16
 ;;^UTILITY(U,$J,358.3,10705,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10705,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,10705,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,10705,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,10706,0)
 ;;=D62.^^68^675^18
 ;;^UTILITY(U,$J,358.3,10706,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10706,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,10706,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,10706,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,10707,0)
 ;;=C92.41^^68^675^19
 ;;^UTILITY(U,$J,358.3,10707,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10707,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,10707,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,10707,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,10708,0)
 ;;=C92.40^^68^675^20
 ;;^UTILITY(U,$J,358.3,10708,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10708,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,10708,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,10708,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,10709,0)
 ;;=D56.0^^68^675^21
 ;;^UTILITY(U,$J,358.3,10709,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10709,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,10709,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,10709,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,10710,0)
 ;;=D63.1^^68^675^23
 ;;^UTILITY(U,$J,358.3,10710,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10710,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,10710,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,10710,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,10711,0)
 ;;=D63.0^^68^675^24
 ;;^UTILITY(U,$J,358.3,10711,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10711,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,10711,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,10711,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,10712,0)
 ;;=D63.8^^68^675^22
 ;;^UTILITY(U,$J,358.3,10712,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10712,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,10712,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,10712,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,10713,0)
 ;;=C22.3^^68^675^25
 ;;^UTILITY(U,$J,358.3,10713,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10713,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,10713,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,10713,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,10714,0)
 ;;=D61.9^^68^675^26
 ;;^UTILITY(U,$J,358.3,10714,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10714,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,10714,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,10714,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,10715,0)
 ;;=D56.1^^68^675^28
 ;;^UTILITY(U,$J,358.3,10715,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10715,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,10715,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,10715,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,10716,0)
 ;;=C83.79^^68^675^29
 ;;^UTILITY(U,$J,358.3,10716,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10716,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,10716,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,10716,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,10717,0)
 ;;=C83.70^^68^675^30
 ;;^UTILITY(U,$J,358.3,10717,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10717,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,10717,1,4,0)
 ;;=4^C83.70
